WO1999006550B1 - 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE - Google Patents

5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE

Info

Publication number
WO1999006550B1
WO1999006550B1 PCT/IB1998/001232 IB9801232W WO9906550B1 WO 1999006550 B1 WO1999006550 B1 WO 1999006550B1 IB 9801232 W IB9801232 W IB 9801232W WO 9906550 B1 WO9906550 B1 WO 9906550B1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nos
cdna
sequences
nucleic acid
Prior art date
Application number
PCT/IB1998/001232
Other languages
French (fr)
Other versions
WO1999006550A3 (en
WO1999006550A2 (en
Inventor
Milne Edwards Jean-Bapti Dumas
Aymeric Duclert
Bruno Lacroix
Original Assignee
Genset Sa
Dumas Milne Edwards Jean Bapti
Aymeric Duclert
Bruno Lacroix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Dumas Milne Edwards Jean Bapti, Aymeric Duclert, Bruno Lacroix filed Critical Genset Sa
Priority to AU85551/98A priority Critical patent/AU8555198A/en
Priority to EP98936590A priority patent/EP1000148A2/en
Priority to JP2000505291A priority patent/JP2001512013A/en
Priority to CA002296287A priority patent/CA2296287A1/en
Publication of WO1999006550A2 publication Critical patent/WO1999006550A2/en
Publication of WO1999006550A3 publication Critical patent/WO1999006550A3/en
Publication of WO1999006550B1 publication Critical patent/WO1999006550B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.

Claims

AMENDED CLAIMS[received by the International Bureau on 19 April 1999 (19.04.99); original claims 1-37 replaced by new claims 1-37 (5 pages)]
1. A purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs; 38-315 or comprising a sequence complementary thereto.
2. The nucleic acid of Claim 1, wherein said nucleic acid is recombinant.
3. A purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 38-315 or one of the sequences complementary thereto, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
4. A purified or isolated nucleic acid comprising at least 15 consecutive bases of one of the sequences of SEQ ID NOs: 38-315 or one of the sequences complementary thereto, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
5. The nucleic acid of Claim 4, wherein said nucleic acid is recombinant.
6. A purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 38-315 or one of the sequences complementary to the sequences of SEQ ID NOs: 38-315, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
7. The nucleic acid of Claim 6, wherein said nucleic acid is recombinant.
8. A purified or isolated nucleic acid encoding a human gene product, said human gene product having a sequence partially encoded by one of the sequences of SEQ ID
NOs: 38-315, with the exception of a purified or isolated nucleic acid consisting of consecutive bases which are situated entirely in the sequences identified as Feature in the corresponding SEQ ID under key: other.
9. A purified or isolated nucleic acid having the sequence of one of SEQ ID NOs: 38-315 or having a sequence complementary thereto.
10. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 38- 15 which encode a signal peptide.
11. A purified or isolated polypeptides comprising a signal peptide encoded by one of the sequences of SEQ ED NOs: 38-315.
12. A vector encoding a fusion protein comprising a polypeptide and a signal peptide, said vector comprising a first nucleic acid encoding a signal peptide encoded by one of the sequences of SEQ ID NOs: 38-315 operably linked to a second nucleic acid encoding a polypeptide.
13. A method of directing the extracellular secretion of a polypeptide or the insertion of a polypeptide into the membrane comprising the steps of: obtaining a vector according to Claim 12; and introducing said vector into a host cell such that said fusion protein is secreted into the extracellular environment of said host cell or inserted into the membrane of said host cell.
14. A method of importing a polypeptide into a cell comprising contacting said cell with a fusion protein comprising a signal peptide encoded by one of the sequences of
SEQ ID NOs: 38-315 operably linked to said polypeptide.
15. A method of making a cDNA encoding a human secretory protein that is partially encoded by one of SEQ ID NOs 38-315, comprising the steps of: obtairώig a cDNA comprising one of the sequences of SEQ ID NOs: 38-315; contacting said cDNA with a detectable probe comprising at least 15 consecutive nucleotides of said sequence of SEQ ID NOs: 38-315 or a sequence complementary thereto under conditions which permit said probe to hybridize to said cDNA; identifying a cDNA which hybridizes to said detectable probe; and isolating said cDNA which hybridizes to said probe.
16. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-315 or a fiagment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 15.
17. The cDNA of Claim 16 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
18. A method of making a cDNA comprising one o the sequences of SEQ ID NOs: 38-315, comprising the steps of: contacting a collection of mRNA molecules from human cells with a first primer capable of hybridizing to the polyA tail of said mRNA; hybridizing said first primer to said polyA tail; reverse transcribing said mRNA to make a first cDNA strand; making a second cDNA strand complementary to said first cDNA strand using at least one primer comprising at least IS nucleotides of one ofthe sequences of SEQ ID NOs 38-315; and isolating the resulting cDNA comprising said first cDNA strand and said second cDNA strand.
19. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38- 15 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 18.
20. The cDNA of Claim 19 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
21. The method of Claim 18, wherein the second cDNA strand is made by; contacting said first cD A strand with a first pair of primers, said first pair of primers comprising a second primer comprising at least 15 consecutive nucleotides of one of the sequences of SEQ ID NOs 38-315 and a third primer having a sequence therein which is included within the sequence of said first primer; perfbπriing a first polymerase chain reaction with said first pair of nested primers to generate a first PCR product; contacting said first PCR product with a second pair of primers, said second pair of primers comprising a fourth primer, said fourth primer comprising at least 15 consecutive nucleotides of said sequence of one of SEQ ID NOs: 38-315, and a fifth primer, said fourth and fifth primers being capable of hybridizing to sequences within said first PCR product; and performing a second polymerase chain reaction, thereby generating a second PCR product. 1 38
22. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ED NOs; 38-315, or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 21.
23. The cDNA of Claim 22 wherein said cDNA comprises the full protein coding sequence partially included in one ofthe sequences of SEQ ID NOs: 38-315.
24. The method of Claim 18 wherein the second cDNA strand is made by: contacting said first cDNA strand with a second primer comprising at least 15 consecutive nucleotides ofthe sequences of SEQ ID NOs: 38-315; hybridizing said second primer to said first strand cDNA; and extending said hybridized second primer to generate said second cDNA strand.
25. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein partially encoded by one of SEQ ID NOs; 38-315 or comprising a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 24.
26. The cDNA of Claim 25, wherein said cDNA comprises the full protein coding sequence partially included in of one ofthe sequences of SEQ ID NOs: 38-315.
27. A method of making a protein comprising one of the sequences of SEQ ID NOs; 316-593, comprising the steps of: obtaining a cDNA encoding the full protein sequence partially included in one ofthe sequences of sequence of SEQ ID NOs: 38-315; inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter; introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA; and isolating said protein.
28. An isolated protein obtainable by the method of Claim 27.
29. A method of obtaining a promoter DNA comprising the steps of: obtaining DNAs located upstream ofthe nucleic acids of SEQ ID NOs: 38-315 or the sequences complementary thereto; 139
screening said upstream DNAs to identify a promoter capable of directing transcription initiation; and isolating said DNA comprising said identified promoter.
30. The method of Claim 29, wherein said obtaining step comprises chromosome walking from said nucleic acids of SEQ ID NOs: 38-315 or sequences complementary thereto.
31. The method of Claim 30, wherein said screening step comprises inserting said upstream sequences into a promoter reporter vector.
32. The method of Claim 30, wherein said screening step comprises identifying motifs in said upstream DNAs which are transcription factor binding sites or transcription start sites.
33. An isolated promoter obtainable by the method of Claim 32.
34. An isolated or purified protein comprising one ofthe sequences of SEQ ID NOs: 316-593.
35. In an array of discrete ESTs or fragments thereof of at least 15 nucleotides in length, the improvement comprising inclusion in said array of at least one ofthe sequences of SEQ ID NOs; 38-315, or one ofthe sequences complementary to the sequences of SEQ ID NOs: 38-315, or a fragment thereof of at least 15 consecutive nucleotides.
36. The array of Claim 35 including therein at least two ofthe sequences of SEQ ID NOs: 38-315, the sequences complementary to the sequences of SEQ ID NOs: 38-315, or fragments thereof of at least 15 consecutive nucleotides.
37. The array of Claim 35 including therein at least five ofthe sequences of SEQ ID NOs; 38-315, the sequences complementary to the sequences of SEQ ID NOs: 38-315, or fragments thereof of at least 15 consecutive nucleotides.
PCT/IB1998/001232 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE WO1999006550A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU85551/98A AU8555198A (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in prostate
EP98936590A EP1000148A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
JP2000505291A JP2001512013A (en) 1997-08-01 1998-07-31 5'EST of secreted protein expressed in prostate
CA002296287A CA2296287A1 (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in prostate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90514497A 1997-08-01 1997-08-01
US08/905,144 1997-08-01

Publications (3)

Publication Number Publication Date
WO1999006550A2 WO1999006550A2 (en) 1999-02-11
WO1999006550A3 WO1999006550A3 (en) 1999-04-29
WO1999006550B1 true WO1999006550B1 (en) 1999-06-03

Family

ID=25420349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001232 WO1999006550A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE

Country Status (5)

Country Link
EP (1) EP1000148A2 (en)
JP (1) JP2001512013A (en)
AU (1) AU8555198A (en)
CA (1) CA2296287A1 (en)
WO (1) WO1999006550A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932678B2 (en) 2015-07-06 2024-03-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053486A1 (en) * 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2000073454A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6656480B2 (en) * 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
NZ337446A (en) 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030059780A1 (en) 1997-06-16 2003-03-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6312922B1 (en) * 1998-02-09 2001-11-06 Genset Complementary DNAs
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
AU2003262114B8 (en) * 1998-02-09 2006-08-03 Serono Genetics Institute S.A. cDNAs encoding secreted proteins
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
GB9807723D0 (en) * 1998-04-08 1998-06-10 Smithkline Beecham Plc Novel compounds
DE19818620A1 (en) * 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New polypeptides and their nucleic acids, useful for treatment of bladder tumor and identification of therapeutic agents
US7193045B2 (en) 1998-05-15 2007-03-20 Genetech, Inc. Polypeptides that induce cell proliferation
AU3952699A (en) * 1998-05-19 1999-12-06 Compugen Ltd. Metabotropic glutamate receptor-like protein and encoding cdna
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (en) 1998-06-01 2009-12-01 Agensys, Inc. NEW TRANSMEMBRANABLE ANTIGENS EXPRESSED IN HUMAN CANCER AND USING THEMSELVES.
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1111046A4 (en) * 1998-09-03 2003-07-02 Takeda Chemical Industries Ltd Novel protein and process for producing the same
EP1114155A2 (en) * 1998-09-17 2001-07-11 Incyte Pharmaceuticals, Inc. Human gpcr proteins
KR100504305B1 (en) 1999-03-23 2005-07-28 제넨테크, 인크. Secreted and Transmembrane polypeptides and Nucleic Acids Encoding the Same
IL145775A0 (en) * 1999-04-12 2002-07-25 Agensys Inc 13 transmembrane protein expressed in prostate cancer
EP1792989A1 (en) * 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
JP2003501072A (en) * 1999-06-07 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 26 human secreted proteins
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US20030022279A1 (en) 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU779667B2 (en) * 1999-06-23 2005-02-03 Curagen Corporation Polynucleotides and polypeptides encoded thereby
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
AU780060B2 (en) * 1999-07-16 2005-02-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
WO2001010902A2 (en) * 1999-08-11 2001-02-15 Curagen Corporation Nucleoc acids and secreted polypeptides encoded thereby
AU7377300A (en) * 1999-09-13 2001-04-17 Curagen Corporation Novel human proteins, polynucleotides encoding them and methods of using the same
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
ATE417104T1 (en) * 1999-10-05 2008-12-15 Agensys Inc G PROTEIN-COUPLED RECEPTOR HIGHLY EXPRESSED IN PROSTATE CANCER AND ITS USES
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6835822B1 (en) 1999-10-28 2004-12-28 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
EP1598671A1 (en) * 1999-10-28 2005-11-23 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
FR2800388A1 (en) * 1999-10-29 2001-05-04 Pf Medicament CLONING, EXPRESSION AND CHARACTERIZATION OF A GENE EXPRESSED IN TUMOR CELLS AND INVOLVED IN REGULATION OF THE IMMUNE RESPONSE
US6485938B1 (en) 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
WO2001036465A2 (en) * 1999-11-16 2001-05-25 Zymogenetics, Inc. Human zven proteins
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20020037513A1 (en) * 2000-03-24 2002-03-28 Rosana Kapeller-Libermann 33338, a novel human ubiquitin hydrolase-like molecule and uses thereof
KR20100029069A (en) * 2000-06-23 2010-03-15 제넨테크, 인크. Eg-vegf nucleic acids and polypeptides and methods of use
WO2002006483A1 (en) 2000-07-18 2002-01-24 Takeda Chemical Industries, Ltd. Novel physiologically active peptide and use thereof
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002062996A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Novel physiologically active peptide and use thereof
AUPR311601A0 (en) * 2001-02-15 2001-03-08 Adp Pharmaceutical Pty Limited Matrix gene expression in chondrogenesis
US7070584B2 (en) 2001-02-20 2006-07-04 Kci Licensing, Inc. Biocompatible wound dressing
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2500772A1 (en) 2002-10-07 2004-04-22 Zymogenetics, Inc. Uses of human zven antagonists
CA2503346C (en) * 2002-11-27 2014-03-18 Agensys, Inc. Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
JP4912144B2 (en) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド Use of BV8 and / or EG-VEGF to promote hematopoiesis
ES2443996T3 (en) 2004-04-22 2014-02-21 Agensys, Inc. Antibodies and molecules derived from them that bind to STEAP-1 proteins
FR2982860B1 (en) * 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies USE OF FIBROMODULIN AND LUMICAN TO INCREASE MUSCLE MASS
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP3337748B2 (en) * 1992-09-25 2002-10-21 財団法人神奈川科学技術アカデミー Method for synthesizing full-length cDNA, method for producing intermediate thereof, and method for producing recombinant vector containing full-length cDNA
FR2733762B1 (en) * 1995-05-02 1997-08-01 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE HAIR OF THE 5 'END OF A RNAM FRAGMENT AND PREPARATION OF RNAM AND COMPLETE DNA
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932678B2 (en) 2015-07-06 2024-03-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
US11939366B2 (en) 2015-07-06 2024-03-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

Also Published As

Publication number Publication date
JP2001512013A (en) 2001-08-21
EP1000148A2 (en) 2000-05-17
WO1999006550A3 (en) 1999-04-29
WO1999006550A2 (en) 1999-02-11
CA2296287A1 (en) 1999-02-11
AU8555198A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
WO1999006550B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
WO1999006552B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
WO1999006548B1 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999006554B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO1999006551B1 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006553B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
US5695937A (en) Method for serial analysis of gene expression
Chu et al. Cloning and characterization of five overlapping cDNAs specific for the human proα 1 (I) collagen chain
CA2336227A1 (en) Genes involved in tolerance to environmental stress
Astell et al. The sequence of the DNAs coding for the mating-type loci of Saccharomyces cerevisiae
JP3334806B2 (en) Sequential analysis of gene expression
Sokolov et al. A rapid and simple PCR-based method for isolation of cDNAs from differentially expressed genes
Konecki et al. Hypoxanthine-guanine phosphoribosyltransferase genes of mouse and Chinese hamster: construction and sequence analysis of cDNA recombinants
ESCANDE et al. Human mucin gene MUC5AC: organization of its 5′-region and central repetitive region
Indik et al. Structure of the 3’region of the human elastin gene: great abundance of Alu repetitive sequences and few coding sequences
WO1999043819B1 (en) Family of maize pr-1 genes and promoters
DE69839426D1 (en) NUCLEOTIDE SEQUENCES CODING FOR SECRETATED POLYPEPTIDES FROM MYCOBACTERIUM, VECTORS CONTAINING THEM, AND APPLICATIONS FOR THE DIAGNOSIS AND PREVENTION OF TUBERCULOSIS
CA2118071A1 (en) Dna encoding limonene synthase from mentha spicata
Sümegi et al. A hierarchic arrangement of the repetitive sequences in the Balbiani ring 2 gene of Chironomus tentans
ATE312929T1 (en) NUCLEOTIDE SEQUENCES CODING FOR THE MDHA GENE FROM CORYNEBACTERIUM GLUTAMICUM
Averboukh et al. Better gel resolution and longer cDNAs increase the precision of differential display
Ajioka et al. The calmodulin-ubiquitin associated genes of Trypanosoma cruzi: their identification and transcription
JP2001516764A5 (en)
WO2000066722B1 (en) Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
Simmler et al. Localization and expression analysis of a novel conserved brain expressed transcript, Brx/BRX, lying within the Xic/XIC candidate region

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2296287

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2296287

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85551/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936590

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998936590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1998936590

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936590

Country of ref document: EP